Newborn screening for X-linked Agammaglobulinemia (XLA) can detect the lack of KRECs within a few days after birth, facilitating an earlier diagnosis for patients with XLA and earlier initiation of treatment.

The non-invasive test from just a single blood spot sample, allows to screen for multiple conditions at once, including SCID, SMA, and XLA, ensuring that affected newborns receive early interventions that can drastically improve their quality of life.